BackgroundReports from centers treating patients with coronavirus disease 2019 (COVID-19) have noted that such patients frequently develop AKI. However, there have been no direct comparisons of AKI in hospitalized patients with and without COVID-19 that would reveal whether there are aspects of AKI risk, course, and outcomes unique to this infection.MethodsIn a retrospective observational study, we evaluated AKI incidence, risk factors, and outcomes for 3345 adults with COVID-19 and 1265 without COVID-19 who were hospitalized in a large New York City health system and compared them with a historical cohort of 9859 individuals hospitalized a year earlier in the same health system. We also developed a model to identify predictors of stage 2 or 3 AKI in our COVID-19.ResultsWe found higher AKI incidence among patients with COVID-19 compared with the historical cohort (56.9% versus 25.1%, respectively). Patients with AKI and COVID-19 were more likely than those without COVID-19 to require RRT and were less likely to recover kidney function. Development of AKI was significantly associated with male sex, Black race, and older age (>50 years). Male sex and age >50 years associated with the composite outcome of RRT or mortality, regardless of COVID-19 status. Factors that were predictive of stage 2 or 3 AKI included initial respiratory rate, white blood cell count, neutrophil/lymphocyte ratio, and lactate dehydrogenase level.ConclusionsPatients hospitalized with COVID-19 had a higher incidence of severe AKI compared with controls. Vital signs at admission and laboratory data may be useful for risk stratification to predict severe AKI. Although male sex, Black race, and older age associated with development of AKI, these associations were not unique to COVID-19.
Background Animal models of kidney disease have linked metabolic acidosis with renal damage. The role of low serum bicarbonate levels in kidney disease progression in humans has not been studied. Study Design Retrospective cohort study. Setting & Participants: Adults visiting a medical clinic in the Bronx, NY from 01/01/01 to 12/31/03 were included in the study (n=5,422) and followed until 6/30/07 Predictor Serum bicarbonate levels Outcomes Kidney disease progression was defined as either a decline in the estimated glomerular filtration rate (eGFR) by 50% or reaching an eGFR of <15 ml/min/1.73m2 (n=337). Measurements Patients’ baseline demographics, comorbidities, laboratory data and socioeconomic status were recorded. Serial outpatient serum creatinines were collected (median, 5 measurements/ person). Results The mean age was 52 years, 69% were women, 45% were African-American, 31% were Hispanic, 21% had diabetes mellitus, 41% had hypertension, and 9% had a baseline eGFR <60 ml/min/1.73m2. Kidney disease progressed by the definition above in 337 patients (6.2%). Compared to the reference group (bicarbonate level 25-26 mEq/L), the hazard ratio for progression after adjustment for potential confounders was 1.54 (95% CI 1.13-2.09) for bicarbonate levels ≤22 mEq/L, 0.97 (95% CI 0.70-1.35) for levels 23-24 mEq/L and 1.14 (95% CI 0.84-1.55) for levels ≥27 mEq/L. (Global p-value for inclusion of serum bicarbonate in the model, 0.01). These results remained similar when using different definitions of the outcome (an eGFR decline by 30%, 1288 outcomes (24%)) or doubling of serum creatinine (268 outcomes (4.9%)). Limitations Data used in study was collected for clinical, not research, purposes. Conclusions Low serum bicarbonate is associated with the progression of kidney disease, independent of baseline eGFR and other clinical, demographic and socioeconomic factors. Prospective studies are needed to confirm this relationship and to evaluate the efficacy of alkali supplements for slowing progression.
BackgroundThe level of body-mass index (BMI) associated with the lowest risk of death remains unclear. Although differences in muscle mass limit the utility of BMI as a measure of adiposity, no study has directly examined the effect of muscle mass on the BMI-mortality relationship.MethodsBody composition was measured by dual-energy x-ray absorptiometry in 11,687 participants of the National Health and Nutrition Examination Survey 1999–2004. Low muscle mass was defined using sex-specific thresholds of the appendicular skeletal muscle mass index (ASMI). Proportional hazards models were created to model associations with all-cause mortality.ResultsAt any level of BMI ≥22, participants with low muscle mass had higher body fat percentage (%TBF), an increased likelihood of diabetes, and higher adjusted mortality than other participants. Increases in %TBF manifested as 30–40% smaller changes in BMI than were observed in participants with preserved muscle mass. Excluding participants with low muscle mass or adjustment for ASMI attenuated the risk associated with low BMI, magnified the risk associated with high BMI, and shifted downward the level of BMI associated with the lowest risk of death. Higher ASMI was independently associated with lower mortality. Effects were similar in never-smokers and ever-smokers. Additional adjustment for waist circumference eliminated the risk associated with higher BMI. Results were unchanged after excluding unintentional weight loss, chronic illness, early mortality, and participants performing muscle-strengthening exercises or recommended levels of physical activity.ConclusionsMuscle mass mediates associations of BMI with adiposity and mortality and is inversely associated with the risk of death. After accounting for muscle mass, the BMI associated with the greatest survival shifts downward toward the normal range. These results provide a concrete explanation for the obesity paradox.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.